Lipid Molecule on T Cells Acts as Hidden Brake in Cancer and Chronic Infection
Phosphatidylserine exposed on exhausted CD8 T cells suppresses immune responses — and blocking it boosts anti-tumor immunity.
Summary
Researchers at Emory University discovered that phosphatidylserine (PS), a lipid normally hidden inside cell membranes, migrates to the outer surface of exhausted CD8 T cells during chronic infection and cancer. This exposed PS acts as a previously unrecognized inhibitory signal — not by directly dampening T cells, but by suppressing dendritic cells that would otherwise activate immune responses. Treating chronically infected mice with a PS-targeting antibody reinvigorated stem-like CD8 T cells, boosting proliferation and viral control. Combining the PS antibody with anti-PD-L1 checkpoint therapy produced synergistic effects. Critically, PD1+ CD8 T cells from human tumors also display exposed PS, suggesting this mechanism is clinically relevant and represents a novel therapeutic target beyond classical protein-based immune checkpoints.
Detailed Summary
T cell exhaustion is a central barrier to effective immunity in cancer and chronic infections like HIV. Research has overwhelmingly focused on protein-based inhibitory receptors — PD1, TIM3, LAG3 — as the drivers of this dysfunction. This study challenges that paradigm by identifying a lipid molecule, phosphatidylserine (PS), as a non-classical inhibitory signal on exhausted CD8 T cells.
PS normally resides on the inner leaflet of the plasma membrane of healthy cells, flipping to the outer surface as a signal of cell death. This team showed that viable, antigen-specific CD8 T cells actively externalize PS during lymphocytic choriomeningitis virus (LCMV) chronic infection in mice. Initial T cell activation triggered early PS exposure, while persistent antigen stimulation sustained it. Transcriptomic and lipidomic profiling confirmed PS accumulation in exhausted CD8 T cells.
To test PS's functional role, researchers administered a PS-targeting antibody (mch1N11) to chronically infected mice. This treatment expanded LCMV-specific CD8 T cell populations, particularly PD1+TCF1+ stem-like progenitor cells, which downregulated quiescence gene programs and increased proliferation. Mechanistically, exposed PS on T cells acted extrinsically — suppressing dendritic cell immunostimulatory activity and thereby limiting CD8 T cell activation. This is a distinct mode of immune suppression from receptor-intrinsic checkpoint pathways.
Combining the PS-targeting antibody with anti-PD-L1 checkpoint blockade synergized to amplify CD8 responses and improve viral control beyond either treatment alone. Importantly, PD1+ CD8 T cells isolated from human tumors also externalized PS, validating clinical relevance.
Caveats include the study's reliance on abstract-level data; full mechanistic detail in human tumor models awaits further investigation. Nevertheless, this work opens a new therapeutic avenue targeting lipid-based immune suppression alongside conventional checkpoint blockade.
Key Findings
- Exhausted CD8 T cells externalize phosphatidylserine (PS) on their surface during chronic LCMV infection in mice.
- Exposed PS suppresses dendritic cell immunostimulatory function, indirectly limiting CD8 T cell responses.
- A PS-targeting antibody reinvigorated stem-like PD1+TCF1+ CD8 T cells, boosting proliferation and viral control.
- Combining PS-targeting antibody with anti-PD-L1 produced synergistic enhancement of CD8 immunity.
- PD1+ CD8 T cells from human tumors also expose PS, confirming translational relevance.
Methodology
Mouse models of chronic LCMV infection were used to study PS externalization and immune function. Transcriptomic and lipidomic analyses characterized PS accumulation in exhausted T cells. Therapeutic interventions included a PS-targeting antibody (mch1N11) alone and in combination with anti-PD-L1, with validation in human tumor-derived CD8 T cells.
Study Limitations
Findings are primarily from a mouse model of viral infection; direct causal evidence in human cancers is not yet established. The abstract does not detail long-term safety or off-target effects of PS-targeting antibodies. Mechanistic details of how PS suppresses dendritic cell function in human tumor microenvironments remain to be fully characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.